Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition

PURPOSE OF REVIEW: The moderate glucose-lowering effect of sodium glucose co-transporter 2 (SGLT2) inhibitors is unlikely to explain SGLT2 inhibitor-mediated beneficial outcomes, and unravelling the underlying mechanisms is a high priority in the research community. Given the dominant pathophysiolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Herat, Lakshini Y., Matthews, Jennifer, Azzam, Omar, Schlaich, Markus P., Matthews, Vance B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Hypertension and Metabolic Syndrome (J Sperati, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942945/
https://www.ncbi.nlm.nih.gov/pubmed/35235172
http://dx.doi.org/10.1007/s11906-022-01170-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942945/
https://www.ncbi.nlm.nih.gov/pubmed/35235172
http://dx.doi.org/10.1007/s11906-022-01170-z

Ejemplares similares